http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 04 Jun 2026 07:41:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html <p align="justify">TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nDtN64l-dimsN3rhheZOwZuB5bkNN6nM9q8t562QmOiEUbnUYE_6tJbWF3zYzkmVmPaRedCp53Ekg4p-YZl-JkeUa-7tAuJPLmwKyRIX-BI=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the <strong>2026 American Diabetes Association Thought Leadership Series </strong>at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films.</p> <p align="justify">The Thought Leadership Film Series is a curated set of films profiling organizations active in research and innovation across the field. The series is designed to increase visibility for groups working http://www.streetinsider.com/Press+Releases/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html Thu, 04 Jun 2026 07:41:00 -0400 ACHFF ARCH O.01688245 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html <p align="justify">TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nDtN64l-dimsN3rhheZOwZuB5bkNN6nM9q8t562QmOiEUbnUYE_6tJbWF3zYzkmVmPaRedCp53Ekg4p-YZl-JkeUa-7tAuJPLmwKyRIX-BI=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the <strong>2026 American Diabetes Association Thought Leadership Series </strong>at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films.</p> <p align="justify">The Thought Leadership Film Series is a curated set of films profiling organizations active in research and innovation across the field. The series is designed to increase visibility for groups working http://www.streetinsider.com/Press+Releases/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html Thu, 04 Jun 2026 07:41:00 -0400 ACHFF ARCH O.01688245 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html <p align="justify">TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nDtN64l-dimsN3rhheZOwZuB5bkNN6nM9q8t562QmOiEUbnUYE_6tJbWF3zYzkmVmPaRedCp53Ekg4p-YZl-JkeUa-7tAuJPLmwKyRIX-BI=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the <strong>2026 American Diabetes Association Thought Leadership Series </strong>at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films.</p> <p align="justify">The Thought Leadership Film Series is a curated set of films profiling organizations active in research and innovation across the field. The series is designed to increase visibility for groups working http://www.streetinsider.com/Press+Releases/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html Thu, 04 Jun 2026 07:41:00 -0400 ACHFF ARCH O.01688245 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html <p align="justify">TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nDtN64l-dimsN3rhheZOwZuB5bkNN6nM9q8t562QmOiEUbnUYE_6tJbWF3zYzkmVmPaRedCp53Ekg4p-YZl-JkeUa-7tAuJPLmwKyRIX-BI=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the <strong>2026 American Diabetes Association Thought Leadership Series </strong>at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films.</p> <p align="justify">The Thought Leadership Film Series is a curated set of films profiling organizations active in research and innovation across the field. The series is designed to increase visibility for groups working http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html Thu, 04 Jun 2026 07:41:00 -0400 ACHFF ARCH O.01688245 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html <p align="justify">TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nDtN64l-dimsN3rhheZOwZuB5bkNN6nM9q8t562QmOiEUbnUYE_6tJbWF3zYzkmVmPaRedCp53Ekg4p-YZl-JkeUa-7tAuJPLmwKyRIX-BI=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the <strong>2026 American Diabetes Association Thought Leadership Series </strong>at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films.</p> <p align="justify">The Thought Leadership Film Series is a curated set of films profiling organizations active in research and innovation across the field. The series is designed to increase visibility for groups working http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html Thu, 04 Jun 2026 07:41:00 -0400 ACHFF ARCH O.01688245 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html <p align="justify">TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nDtN64l-dimsN3rhheZOwZuB5bkNN6nM9q8t562QmOiEUbnUYE_6tJbWF3zYzkmVmPaRedCp53Ekg4p-YZl-JkeUa-7tAuJPLmwKyRIX-BI=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company will be featured in the <strong>2026 American Diabetes Association Thought Leadership Series </strong>at their 86th scientific sessions in New Orleans June 5th–8th, 2026, which highlights programs, case studies, and best practices in diabetes in a set of short films.</p> <p align="justify">The Thought Leadership Film Series is a curated set of films profiling organizations active in research and innovation across the field. The series is designed to increase visibility for groups working http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+Featured+in+American+Diabetes+Association+Thought+Leadership+Series+at+the+2026+Scientific+Sessions+in+New+Orleans/26602499.html Thu, 04 Jun 2026 07:41:00 -0400 ACHFF ARCH O.01688245 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Press+Releases/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521 http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html <p align="justify">TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-pxYStEMknQf6Zpky-wzh2RmsVSxLeM6AihZRf45qN7gXIPkn0yrKFrWyq3gBk5vRf7dXJuEXKfGTn_2ItjRZiyg0A8_2mq8QlL6Q23-6NU=" rel="nofollow" target="_blank">Arch Biopartners Inc</a>. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ap6-Bsq_W3eXzJWlxUPcvHu0bbqPMjTVuWMrs5ya9DgdHaOgHGTnIgTE0iGUdLUkDuKh2eBn2_FhyrX7n3oePo2rCOyYUFb3zQ2HUX7kThCWsJagzXgThq9nWCkeWbBSckykIHR77rhCk9qDqpRYXA==" rel="nofollow" target="_blank">Phase II trial</a> evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).</p> <p align="justify">Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada.</p> <p align="justify">Patient recruitment into the trial http://www.streetinsider.com/Globe+Newswire/Arch+Biopartners+announces+Royal+Columbian+Hospital+has+dosed+its+first+patient+in+its+Phase+II+cardiac+surgery-associated+AKI+trial/26538361.html Fri, 22 May 2026 06:50:00 -0400 A.01718595 A.36078215 A.50202421 A.60012012 ACHFF ARCH O.00786770 O.01688245 O.02555813 O.20847516 O.50605521